Development of the recombinant tissue factor for coagulation testing

MBU-Technology LLC has been implementing the project on developing recombinant heparinase I as an indispensable component mainly used for coagulation testing and heparin removal before doing research since January 2019.

The use of heparin as an anticoagulant prevents from obtaining adequate activated partial thromboplastin time (APTT), Thromboelastography and other tests results. Pre-treatment of the studied plasma with recombinant heparinase leads to disintegration of the heparin remains and recovery of the sample coagulologic parameters.